Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 6:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Keratitis Clear all
Suspended Not applicable Interventional Accepts healthy volunteers

QST for Corneal Nerve Function

NCT05758753
View directory record Official record
Conditions
Corneal Disease, Neuropathy, Dry Eye Disease, Neurotrophic Keratitis
Interventions
Quantitative Sensory Test
Device
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Jun 10, 2026, 6:30 PM EDT
Completed Not applicable Interventional

Ultraviolet-A and Riboflavin Treatment for Infectious Keratitis

NCT01739673
View directory record Official record
Conditions
Infectious Keratitis
Interventions
Ultraviolet-A and riboflavin
Other
Lead sponsor
Cxlusa
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
6
States / cities
Scottsdale, Arizona • West Hills, California • Littleton, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Jun 10, 2026, 6:30 PM EDT
Completed Phase 2 Interventional

Safety and Effectiveness of the PXL Platinum 330 System for Corneal Collagen Cross-Linking in Eyes With Corneal Thinning Position

NCT04213885
View directory record Official record
Conditions
Keratoconus, Unstable, Ectasia Corneal, Bacterial Keratitis
Interventions
PXL 330 Platinum device/Riboflavin
Combination Product
Lead sponsor
Eye Specialists of Indiana
Other
Eligibility
12 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Jun 10, 2026, 6:30 PM EDT
Recruiting Phase 2 Interventional

Efficacy of Locally Delivered Allogeneic Mesenchymal Stromal Cells

NCT05705024
View directory record Official record
Conditions
Corneal Ulcer
Interventions
Mesenchymal Stromal Cells, Control Solution
Biological · Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Jun 10, 2026, 6:30 PM EDT
Completed Phase 4 Interventional Results available

Steroids for Corneal Ulcers Trial

NCT00324168
View directory record Official record
Conditions
Corneal Ulcer, Eye Infections, Bacterial
Interventions
Antibiotics, Topical corticosteroid, Placebo
Drug
Lead sponsor
Thomas M. Lietman
Other
Eligibility
16 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
2
States / cities
San Francisco, California • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Jun 10, 2026, 6:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Systane Versus Saline in Maintaining Tear Film Stability at Determined Time Points

NCT00345241
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
Systane Ocular Drops (OTC), Placebo - Saline Drops
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 88 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2008 · Synced Jun 10, 2026, 6:30 PM EDT
Not listed Phase 2Phase 3 Interventional

Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Previously Untreated Corneal Ulcers

NCT05255107
View directory record Official record
Conditions
Keratitis, Corneal Ulcer
Interventions
Standard of Care Therapy + CXL + Riboflavin 0.23% L Solution, Standard of Care Therapy + Sham CXL + Artificial Tears
Combination Product · Other
Lead sponsor
Peschke GmbH
Industry
Eligibility
18 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
12
States / cities
Littleton, Colorado • Fort Myers, Florida • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Jun 10, 2026, 6:30 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease

NCT02813265
View directory record Official record
Conditions
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Interventions
KPI-121 0.25% Ophthalmic Suspension, Vehicle of KPI-121 0.25% Ophthalmic Suspension
Drug
Lead sponsor
Kala Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
918 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
60
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 53 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Jun 10, 2026, 6:30 PM EDT
Completed Phase 4 Interventional Results available

Impact of Acthar on Everyday Life of Participants With Severe Keratitis

NCT04169061
View directory record Official record
Conditions
Keratitis
Interventions
Acthar
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
9
States / cities
Phoenix, Arizona • Glendale, California • Newport Beach, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Jun 10, 2026, 6:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pilot Study to Investigate the Feasibility, Reliability and Efficacy of Utilizing OCT to Automate PROSE Fitting

NCT04649177
View directory record Official record
Conditions
Keratoconus, Ocular Surface Disease, Pellucid Marginal Corneal Degeneration, Ectasia, Corneal Trauma, Corneal Scar, Dry Eye Syndromes, Keratoconjunctivitis Sicca, Sjogren's Syndrome
Interventions
Ocular surface optical coherence tomography
Device
Lead sponsor
Boston Sight
Other
Eligibility
21 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Jun 10, 2026, 6:30 PM EDT
Recruiting Phase 2 Interventional

Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease

NCT06919081
View directory record Official record
Conditions
Persistent Corneal Epithelial Defect, Corneal Epithelial Disorders
Interventions
Allogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretome, Vehicle Control
Drug · Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Jun 10, 2026, 6:30 PM EDT
Completed Phase 3 Interventional Results available

Mycotic Ulcer Treatment Trial I

NCT00996736
View directory record Official record
Conditions
Corneal Ulcer, Eye Infections, Fungal
Interventions
Natamycin, Voriconazole
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
16 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Jun 10, 2026, 6:30 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of RX-10045 on the Signs and Symptoms of Dry Eye

NCT00799552
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
RX-10045, Placebo
Drug
Lead sponsor
Resolvyx Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 23, 2010 · Synced Jun 10, 2026, 6:30 PM EDT
Completed No phase listed Observational

Corneal Nerves After Treatment With Cenegermin

NCT04627571
View directory record Official record
Conditions
Neurotrophic Keratitis
Interventions
Cenegermin Ophthalmic Solution [Oxervate]
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 99 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2025 · Synced Jun 10, 2026, 6:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Goblet Cell Response and Dry Eye Symptoms After PRK and LASIK

NCT00411827
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
PRK with conjunctival impression cytology before and after surgery, LASIK with conjunctival impression cytology before and after surgery
Procedure
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
21 Years to 40 Years
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Jun 10, 2026, 6:30 PM EDT
Completed Phase 3 Interventional Results available

Vehicle-Controlled Study of SkQ1 as Treatment for Dry-eye Syndrome

NCT04206020
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
SkQ1 Vehicle Solution, SkQ1 Ophthalmic Solution
Drug
Lead sponsor
Mitotech, SA
Industry
Eligibility
18 Years and older
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Sun City West, Arizona • Andover, Massachusetts • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Jun 10, 2026, 6:30 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

DOMPE -MT Neurotrophic Keratitis

NCT06947850
View directory record Official record
Conditions
Dry Eye, Neurotrophic Keratitis
Interventions
Cenegermin Ophthalmic Solution [Oxervate]
Drug
Lead sponsor
Toyos Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Jun 10, 2026, 6:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Acupuncture Treatment of Dry Eye

NCT00554879
View directory record Official record
Conditions
Keratoconjunctivitis Sicca, Xeropthalmia
Interventions
Acupuncture, Sham acupuncture
Procedure
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 29, 2011 · Synced Jun 10, 2026, 6:30 PM EDT
Completed Phase 3 Interventional Results available

Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal Keratoconjunctivitis

NCT01751126
View directory record Official record
Conditions
Vernal Keratoconjunctivitis
Interventions
NOVA22007 ''Ciclosporin'', Placebo
Drug
Lead sponsor
Santen SAS
Industry
Eligibility
4 Years to 18 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Glendale, California • Irvine, California • Rancho Cordova, California + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2022 · Synced Jun 10, 2026, 6:30 PM EDT
Completed Phase 3 Interventional Results available

The Mycotic Ulcer Treatment Trial II: A Randomized Trial Comparing Oral Voriconazole vs Placebo

NCT00997035
View directory record Official record
Conditions
Corneal Ulcer, Eye Infections, Fungal
Interventions
Voriconazole, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
16 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Jun 10, 2026, 6:30 PM EDT
Completed Phase 3 Interventional Results available

Study of SkQ1 as Treatment for Dry-eye Syndrome

NCT03764735
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Low Dose - SkQ1, High dose - SkQ1, SkQ1 (Vehicle)
Drug
Lead sponsor
Mitotech, SA
Industry
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
Phoenix, Arizona • Newport Beach, California • Louisville, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Jun 10, 2026, 6:30 PM EDT
Completed Phase 2 Interventional Results available

REC 0/0559 Eye Drops for Treatment of Moderate and Severe Neurotrophic Keratitis in Adult Patients

NCT04276558
View directory record Official record
Conditions
Neurotrophic Keratitis
Interventions
Udonitrectag, Vehicle
Drug · Other
Lead sponsor
RECORDATI GROUP
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
9
States / cities
Crystal River, Florida • Gainesville, Florida • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Jun 10, 2026, 6:30 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Lifitegrast 5% Ophthalmic Solution and Contact Lens Dryness

NCT03686878
View directory record Official record
Conditions
Contact Lens, Contact Lens Discomfort, Contact Lens Dryness
Interventions
Lifitegrast
Drug
Lead sponsor
EV Clinical Trials
Other
Eligibility
21 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Jun 10, 2026, 6:30 PM EDT
Completed Phase 4 Interventional

A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome

NCT02139033
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
Retaine™
Drug
Lead sponsor
Ocusoft, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 10, 2014 · Synced Jun 10, 2026, 6:30 PM EDT